Dr Jane K Osbourn OBE FMed Sc

Jane is Chief Executive Officer at Alchemab Therapeutics, which focusses on identifying self-protective antibodies as therapies for neurodegeneration and oncology. She has worked in antibody drug discovery for over 25 years and was an early employee of Cambridge Antibody Technology, which became MedImmune, the biologics arm of AstraZeneca. There she contributed to the development of phage display technology, authored many key publications and patents and contributed to the discovery and development of eight marketed biologics drugs. She is passionate about the development of the biotechnology sector and served as Chair of the UK BioIndustry Association from 2015-2019. In 2019 she was awarded an OBE for services to drug discovery, development and biotechnology, and was the first female recipient of the Scrip Lifetime Achievement Award for her contribution to the pharma industry.